Exelixis NASDAQ: EXEL President and CEO Michael Morrissey said the company is focused on expanding i

Exelixis, Inc. (EXEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Exelixis NASDAQ: EXEL executives outlined plans to continue expanding the CABOMETYX franchise while

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the

Integrated Wealth Concepts LLC reduced its position in shares of Exelixis, Inc. (NASDAQ: EXEL) by 25

Exelixis NASDAQ: EXEL executives outlined a franchise-focused growth strategy centered on expanding

The FDA extended its review of Exelixis' zanzalintinib by three months, but no new clinical failure

On Friday, the U.S. Food and Drug Administration (FDA) extended the review period for Exelixis Inc.‘

FDA extends Exelixis NDA review for zanzalintinib to March 2027. Analyst evaluates stock volatility

The ‌U.S. Food and Drug Administration has extended the review of ​Exelixis' experimental colorectal

In response to an FDA information request, Exelixis had submitted updated safety and efficacy data,

Baird Financial Group Inc. increased its holdings in shares of Exelixis, Inc. (NASDAQ: EXEL) by 7,45

Exelixis, Inc. (EXEL) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Exelixis, Inc. (EXEL) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company managem

Exelixis is downgraded from "Strong Buy" to "Hold" due to lowered 2026 revenue guidance and mixed cl

[url="]Exelixis, Inc.[/url] (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exeli

Exelixis, Inc. (NASDAQ:EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN L

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit

Exelixis, Inc. (EXEL) shares enjoying institutional support – up 43.5% in a year.

Allworth Financial LP bought a new position in shares of Exelixis, Inc. (NASDAQ: EXEL) in the second

BMO Capital analyst David Lebowitz initiates coverage on Exelixis (NASDAQ:EXEL) with a Market Per

Truist Securities analyst Gregory Renza maintains Exelixis (NASDAQ:EXEL) with a Hold and lowers t

Stifel analyst Stephen Willey maintains Exelixis (NASDAQ:EXEL) with a Hold and raises the price t

Exelixis (NASDAQ:EXEL) lowers FY2026 sales outlook from $2.525 billion-$2.625 billion to $2.500 bill

Exelixis (NASDAQ:EXEL) reported quarterly earnings of $0.91 per share which beat the analyst consens

Morgan Stanley analyst Sean Laaman maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raise

Barclays analyst Etzer Darout maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raises the

Wells Fargo analyst Eva Fortea Verdejo maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and r

RBC Capital analyst Leonid Timashev maintains Exelixis (NASDAQ:EXEL) with a Sector Perform and ra

Truist Securities analyst Gregory Renza maintains Exelixis (NASDAQ:EXEL) with a Hold and raises t

UBS analyst Ashwani Verma maintains Exelixis (NASDAQ:EXEL) with a Neutral and raises the price ta

HC Wainwright & Co. analyst Robert Burns reiterates Exelixis (NASDAQ:EXEL) with a Buy and mai

Wall Street analysts change outlook on top names, with downgrades and initiations. See analyst ratin

Truist Securities analyst Gregory Renza downgrades Exelixis (NASDAQ:EXEL) from Buy to Hold and ra

Citizens analyst Silvan Turkcan maintains Exelixis (NASDAQ:EXEL) with a Market Outperform and rai

Exelixis reported final STELLAR-303 data showing a survival trend for zanzalintinib combo in metasta

Exelixis, Inc. (NASDAQ:EXEL) today announced results from the final analysis of the dual primary end

STELLAR-316 is a planned phase 3 pivotal trial in patients with resected stage II/III colorectal can

Top Wall Street analysts changed their outlook on top names. See all rating changes, including upgra

HC Wainwright & Co. analyst Robert Burns maintains Exelixis (NASDAQ:EXEL) with a Buy and rais

TD Cowen analyst Yaron Werber maintains Exelixis (NASDAQ:EXEL) with a Buy and raises the price ta

Morgan Stanley analyst Sean Laaman maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raise

Stifel analyst Stephen Willey maintains Exelixis (NASDAQ:EXEL) with a Hold and raises the price t

Wells Fargo analyst Eva Fortea Verdejo maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and r

Dr. Morrissey continued: "Our R&D organization is on track to deliver multiple milestones th

Exelixis (NASDAQ:EXEL) affirms FY2026 sales outlook from $2.525 billion-$2.625 billion to $2.525 bil

Exelixis (NASDAQ:EXEL) reported quarterly earnings of $0.87 per share which beat the analyst consens